# Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

> **NCT04966871** · PHASE1 · COMPLETED · sponsor: **Sanaria Inc.** · enrollment: 54 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** PfSPZ Vaccine
- **BIOLOGICAL:** PfSPZ Challenge (7G8) for CHMI
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT04966871
- **Lead sponsor:** Sanaria Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-27
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04966871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04966871, "Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04966871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*